Indena has announced that it will attending this year’s CPHI.
The event — which will be held in Milan from the 8–10 October — allows industry members to discover the latest trends, technologies and solutions within the pharmaceutical industry.
The CDMO, which will be exhibiting at Booth C9 in Hall 4, will present its latest advancements in ADC payload production.
This includes the most recent equipment implemented at its main Italian plant.
As well as Indiana’s technological innovations, the company will showcase its novel APIs, including resiniferatoxin, squalene and cytisine — to name a few.
According to the company, the market for HPAPIs is growing, as the unmet needs for patients with complex diseases remains an issue.
Therefore, Indena is catering to this demand by leveraging its years of experience.
The company will also be on hand to discuss its role in the manufacture of linker-payloads, as well as their linker-payload clinical trial and scale-up support services.
Indena’s Chief Commercial Officer, Stefano Togni, commented: “Indena is truly delighted to welcome its guests to Milan this year. The event will be a great opportunity to discuss business, share ideas and projects and talk about innovation and the future of the pharmaceutical sector; particularly of CDMO activities which have always been a priority for Indena.”
“Indena’s researchers and managers will be available for customers and prospects to present all the latest updates on the company's facilities, technologies, and solutions for pharmaceutical and biotech companies. For us, working in the CDMO sector means establishing a true partnership, listening to and embracing our client's challenges in order to help them achieve their goals”.
R&D Director at Indena, Pietro Allegrini, added: “Antibody Drug Conjugates (ADCs) represent a significant advancement in targeted therapy, holding immense promise for the pharmaceutical industry. Our expertise includes payloads for ADCs with a backward integration on fermentation for toxins requiring this step,”
“At CPHI 2024 we’ll all be on hand to discuss the expanded production capability of our main site at Settala, which will allow us to enlarge our capacity by up to 10x.”
From rainforest to clinic
Indena’s Director of R&D and Process Research, Federico Peterlongo, will also give a talk, entitled: “From the rainforest to the clinic: turning a high-potency rare natural product into an anti-cancer API”.
The presentation will be held on October 8 at 15:15, at Hall 5, Stand 5B49.
